Recent Insider Transactions • Jul 21
Independent Director recently bought €60k worth of stock On the 15th of July, Eva Elmstedt bought around 25k shares on-market at roughly €2.42 per share. This transaction amounted to 26% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €3.7m more in shares than they have sold in the last 12 months. Reported Earnings • Jul 16
Second quarter 2026 earnings released: EPS: kr0.46 (vs kr0.34 in 2Q 2025) Second quarter 2026 results: EPS: kr0.46 (up from kr0.34 in 2Q 2025). Revenue: kr2.76b (up 3.0% from 2Q 2025). Net income: kr125.0m (up 36% from 2Q 2025). Profit margin: 4.5% (up from 3.4% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Annonce • Jul 14
Arjo AB (publ) to Report Q1, 2027 Results on Apr 16, 2027 Arjo AB (publ) announced that they will report Q1, 2027 results on Apr 16, 2027 Annonce • Apr 01
Arjo AB (publ) to Report Fiscal Year 2026 Results on Jan 30, 2027 Arjo AB (publ) announced that they will report fiscal year 2026 results on Jan 30, 2027 Annonce • Mar 24
Arjo AB (publ) to Report Fiscal Year 2025 Final Results on Mar 31, 2026 Arjo AB (publ) announced that they will report fiscal year 2025 final results on Mar 31, 2026 Annonce • Mar 19
Arjo AB (Publ) Proposes Cash Dividend, Payable from 29 April 2026 The Board of Directors of Arjo AB (publ) have proposed that a dividend of SEK 0.95 per share shall be declared. As record date for the dividend, the Board proposes 24 April 2026. If the AGM resolves in accordance with the proposal, the dividend is expected to be distributed by Euroclear Sweden AB starting 29 April 2026. Annonce • Jan 31
Arjo AB (publ), Annual General Meeting, Apr 22, 2026 Arjo AB (publ), Annual General Meeting, Apr 22, 2026. Annonce • Jan 30
Arjo Propose Dividend for 2025 Arjo proposed a dividend per share of SEK 0.95 (0.95), corresponding to approximately SEK 259 million. Annonce • Oct 23
Arjo AB (publ) (OM:ARJO B) acquired Slingcare B.V. for SEK 19 million. Arjo AB (publ) (OM:ARJO B) acquired Slingcare B.V. for SEK 19 million on October 1, 2025. A cash consideration of SEK 19 million will be paid by Arjo AB (publ). As part of consideration, SEK 19 million is paid towards common equity of Slingcare B.V.
For the period ending December 31, 2024, Slingcare B.V. reported total revenue of SEK 6 million.
Arjo AB (publ) (OM:ARJO B) completed the acquisition of Slingcare B.V. for SEK 19 million on October 1, 2025. Annonce • Sep 29
Arjo AB (publ) to Report Q3, 2025 Results on Oct 22, 2025 Arjo AB (publ) announced that they will report Q3, 2025 results at 7:00 AM, Central European Standard Time on Oct 22, 2025 Annonce • Aug 28
Arjo AB Appoints Christofer Carlsson as Permanent CFO, Effective September 1, 2025 Arjo AB announced that Christofer Carlsson, who has been interim CFO since January 20, 2025, has been appointed permanent CFO of the company starting September 1, 2025. Christofer has been with Arjo since 2017 and was previously responsible for Corporate Control, encompassing functions such as Group Accounting, Tax, and Business and Sustainability Controlling. Annonce • Jul 11
Arjo AB (Publ) Announces Earnings Guidance for the Year 2025 Arjo AB (publ) announced earnings guidance for the year 2025. For the year, Organic sales growth is expected to be within the Group's target interval of 35%. Annonce • May 01
Arjo AB (Publ) Provides Sales Guidance for the Year 2025 Arjo AB (publ) provided sales guidance for the year 2025. Organic sales growth for 2025 is expected to be within the Group's target interval of 3-5%. Annonce • Apr 30
Arjo Approves Dividend for 2024, Payable from May 7, 2025 In accordance with the proposal of the Board of Directors and the CEO of Arjo AB (publ), the Annual General Meeting resolved to declare a dividend of SEK 0.95 per share 2 May 2025 was determined as record date for dividend and the dividend is expected to be distributed by Euroclear Sweden AB starting 7 May 2025. Annonce • Apr 16
Arjo Strengthens Leading Position in Patient Handling by Introducing the New Maxi Move 5 Patient Floor Lift Arjo announced the launch of Maxi Move 5®?, the latest generation of one of the company's best-selling products. The new top-of-the-line mobile patient floor lift features several innovative technical solutions designed to help reduce caregiver injuries and optimize efficiencies in care situations. For five decades Arjo has been driving innovation within mobile patient floor lifts and remains in a leading position in the patient handling segment, and once again breaks new ground with Maxi Move 5. Patient handling remains one of Arjo's core product categories, representing approximately 26% of the company's total sales in 2024, which makes it the single largest category within the full portfolio. The launch of Maxi Move 5 is the second major product launch from Arjo in 2025, following the Symbliss®? bath system introduced earlier this year. Maxi Move 5 is intended for lifting, transferring and repositioning patients and residents within both hospitals and long-term care settings. It can also be used to facilitate hygiene care and rehabilitation exercises. The comprehensive range of unique features and functions includes the new Arjo Motion Assist®?. Operated via touch sensors on the caregiver handle that react to the carer's push, pull and pivoting motions, it enables efficient, controlled and intuitive transfers, with minimal effort from the caregiver. In addition, the Powered Dynamic Positioning System enables accurate seated positioning, supporting care flow efficiencies during transfers operated via the hand control or control panel. An independent clinical lab study shows that Maxi Move 5 reduces the accumulated forces required to complete a patient transfer by up to 68%, compared with competitor devices included in the study. Currently available in the United States, Germany, France and the Netherlands, Maxi Move 5 is scheduled to be launched in about 40 countries by the end of 2025. Annonce • Mar 27
Arjo Announces Executive Changes Arjo has appointed Eva Brike as new EVP Human Resources & Sustainability starting June 1, 2025. Eva succeeds Marion Gullstrand, who after a long operational career has chosen to pursue new opportunities. Eva Brike most recently held the position of Vice President People & Culture at Atos Medical, part of Coloplast. She has a solid background that also includes positions at Rosti Group and Resurs Bank. Marion Gullstrand has been responsible for HR and sustainability at Arjo since before the IPO in 2017 and has previously worked for many years at Getinge. Eva Brike takes office on June 1. Marion Gullstrand will ensure a smooth transition and will leave Arjo at the end of June. Annonce • Jan 31
Arjo AB (publ), Annual General Meeting, Apr 29, 2025 Arjo AB (publ), Annual General Meeting, Apr 29, 2025. Location: malmo Sweden Annonce • Jan 21
Arjo Introduces Symbliss - the Next-Generation Integrated Bathing System Arjo presenting Symbliss®,an innovative assisted bathing system setting a new standard in the healthcare industry. Symbliss supports workflows that reduce caregiver injuries, optimize efficiencies in care settings and enables person-centered wellness experiences. The company has a longstanding tradition of developing hygiene solutions, with the systematic approach to both bathing and transfer equipment going back more than 50 years. Symbliss is a height-adjustable integrated bathing system consisting of a bathtub and a bath chair, with a comprehensive range of unique features and functions. The system is designed according to dementia-friendly principles and has received the highest rating from the Dementia Services Development Centre (DSDC) at the University of Stirling in Scotland. An independent study1 confirms that Arjo's Symbliss bath and chair are ergonomically safe to use by a single caregiver across mobility levels. This helps to improve efficiencies in care workflows, paving the way for time and resource savings. Symbliss is currently available in Belgium and Sweden, with launches in the US, Canada, UK and western European countries scheduled for the first quarter of 2025. Annonce • Jan 20
Arjo Announces Chief Financial Officer Changes Arjo announced that Due to Niclas Sjöswärd taking on the role of acting CEO for Arjo following Joacim Lindoff's departure from the company, Christofer Carlsson has been appointed interim CFO, effective January 20, 2025. Christofer currently holds the position of Vice President Corporate Control at Arjo, encompassing functions such as Group Accounting, Tax, and Business and Sustainability Controlling. Christofer has been with Arjo since 2017 and has previous experience from finance positions at Gambro and BE Group among others. Annonce • Jan 15
Arjo AB (Publ) Announces CEO Changes Arjo AB (publ) announced The Board of Directors of Arjo and Joacim Lindoff have come to an agreement which implicates Joacim leaving his position as CEO of Arjo, a role he has held since 2017. Niclas Sjöswärd, currently CFO of Arjo, has been appointed interim CEO. The process of recruiting a new CEO will be initiated immediately. Annonce • Jan 14
Arjo AB (Publ) Announces Resignation of Joacim Lindoff as President Arjo AB (publ) announced The Board of Directors of Arjo and Joacim Lindoff have come to an agreement which implicates Joacim leaving his position as President of Arjo, a role he has held since 2017. Niclas Sjöswärd, currently CFO of Arjo, has been appointed interim President. Reported Earnings • Oct 20
Third quarter 2024 earnings released: EPS: kr0.27 (vs kr0.30 in 3Q 2023) Third quarter 2024 results: EPS: kr0.27 (down from kr0.30 in 3Q 2023). Revenue: kr2.73b (down 1.5% from 3Q 2023). Net income: kr73.0m (down 9.9% from 3Q 2023). Profit margin: 2.7% (down from 2.9% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings. Annonce • Sep 25
Arjo AB (publ) (OM:ARJO B) signed an agreement to acquire TECH MED. Arjo AB (publ) (OM:ARJO B) signed an agreement to acquire TECH MED on September 24, 2024. As of 2023, Tech Med had a turnover of approximately €2.25 million.
The closing of the acquisition of Tech Med is subject to customary approvals from authorities which are expected during the fourth quarter of 2024. Annonce • Sep 24
Arjo AB (publ) (OM:ARJO B) agreed to acquire GerroMed GmbH. Arjo AB (publ) (OM:ARJO B) agreed to acquire GerroMed GmbH on September 24, 2024.
For the period ending December 31, 2023, GerroMed GmbH reported total revenue of SEK 30 million.
The transaction is subject to approval by regulatory board / committee. The transaction is expectd to be completed in the fourth quarter of 2024. Reported Earnings • Jul 14
Second quarter 2024 earnings released: EPS: kr0.44 (vs kr0.38 in 2Q 2023) Second quarter 2024 results: EPS: kr0.44 (up from kr0.38 in 2Q 2023). Revenue: kr2.81b (up 4.6% from 2Q 2023). Net income: kr120.0m (up 15% from 2Q 2023). Profit margin: 4.3% (up from 3.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Annonce • Jul 12
Arjo AB (Publ) Provides Organic Net Sales Guidance for the Full Year 2024 Arjo AB (publ) provided organic net sales guidance for the full year 2024. The outlook 2024, where, given the solid start in the first half year, continue to guide for an organic net sales increase well within target interval of 3% to 5%. Based on this solid start to the year, the company feel comfortable with the organic net sales outlook for the full year. Annonce • May 18
Arjo Provides Sales Guidance for the Year 2024 Arjo provided sales guidance for the year 2024. For the year, the company expects organic net sales growth to be between 3% to 5%. Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: kr0.48 (vs kr0.41 in 1Q 2023) First quarter 2024 results: EPS: kr0.48 (up from kr0.41 in 1Q 2023). Revenue: kr2.76b (up 4.6% from 1Q 2023). Net income: kr132.0m (up 17% from 1Q 2023). Profit margin: 4.8% (up from 4.3% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 20% per year. New Risk • Apr 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (45% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.0% average weekly change). Upcoming Dividend • Apr 12
Upcoming dividend of kr0.90 per share Eligible shareholders must have bought the stock before 19 April 2024. Payment date: 25 April 2024. Payout ratio is a comfortable 51% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (1.7%). Reported Earnings • Mar 24
Full year 2023 earnings released: EPS: kr1.76 (vs kr1.65 in FY 2022) Full year 2023 results: EPS: kr1.76 (up from kr1.65 in FY 2022). Revenue: kr11.0b (up 10.0% from FY 2022). Net income: kr480.0m (up 6.9% from FY 2022). Profit margin: 4.4% (down from 4.5% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 13% per year. Annonce • Mar 13
Arjo AB (Publ) Proposes Dividend, Payable on 25 April 2024 The Board of Arjo AB (publ) and the CEO have proposed that a dividend of SEK 0.90 per share shall be declared. As record date for the dividend, the Board proposes 22 April 2024. If the AGM resolves in accordance with the proposal, the dividend is expected to be distributed by Euroclear Sweden AB starting 25 April 2024. Declared Dividend • Feb 04
Dividend of kr0.90 announced Shareholders will receive a dividend of kr0.90. Ex-date: 19th April 2024 Payment date: 25th April 2024 Dividend yield will be 21%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (51% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 10% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 78% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annonce • Jan 31
Arjo AB (publ) to Report Fiscal Year 2023 Final Results on Mar 21, 2024 Arjo AB (publ) announced that they will report fiscal year 2023 final results at 9:00 AM, Central European Standard Time on Mar 21, 2024 Reported Earnings • Jan 30
Full year 2023 earnings released: EPS: kr1.76 (vs kr1.64 in FY 2022) Full year 2023 results: EPS: kr1.76 (up from kr1.64 in FY 2022). Revenue: kr11.0b (up 10.0% from FY 2022). Net income: kr480.0m (up 7.4% from FY 2022). Profit margin: 4.4% (down from 4.5% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year. Recent Insider Transactions • Oct 24
Independent Chairman of the Board recently bought €154k worth of stock On the 20th of October, Johan Malmquist bought around 50k shares on-market at roughly €3.07 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €182k. Johan has been a buyer over the last 12 months, purchasing a net total of €693k worth in shares. Annonce • Oct 20
Arjo AB (Publ) Provides Financial Outlook for 2023 Arjo AB (publ) provided financial outlook for 2023. For the period company expected, based on current visibility of the market, the organic net sales growth for 2023 to be within the group's target interval of 3% to 5%. The company continue to expect 2023 to be a year with net sales and profitability improvements versus 2022. Reported Earnings • Oct 20
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr2.78b (up 10% from 3Q 2022). Net income: kr98.0m (up 14% from 3Q 2022). Profit margin: 3.5% (up from 3.4% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Recent Insider Transactions • Aug 13
Independent Chairman of the Board recently bought €182k worth of stock On the 10th of August, Johan Malmquist bought around 50k shares on-market at roughly €3.65 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Johan has been a buyer over the last 12 months, purchasing a net total of €539k worth in shares. Reported Earnings • Jul 14
Second quarter 2023 earnings released: EPS: kr0.37 (vs kr0.38 in 2Q 2022) Second quarter 2023 results: EPS: kr0.37 (down from kr0.38 in 2Q 2022). Revenue: kr2.69b (up 12% from 2Q 2022). Net income: kr102.0m (down 1.9% from 2Q 2022). Profit margin: 3.8% (down from 4.3% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 11% per year. Annonce • May 09
Arjo AB (publ) Announces Resignation of Daniel Fäldt as CFO Arjo AB (publ) announced that CFO Daniel Fäldt has due to family reasons decided to leave his position as CFO and member of the Arjo Management team with immediate effect. The process to find a successor starts immediately. Until a successor is in place, Joacim Lindoff, President & CEO, will hold the interim responsibility for the Group's finance function. Reported Earnings • Apr 20
First quarter 2023 earnings released: EPS: kr0.35 (vs kr0.60 in 1Q 2022) First quarter 2023 results: EPS: kr0.35 (down from kr0.60 in 1Q 2022). Revenue: kr2.64b (up 11% from 1Q 2022). Net income: kr95.0m (down 42% from 1Q 2022). Profit margin: 3.6% (down from 6.9% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Upcoming Dividend • Apr 14
Upcoming dividend of kr0.85 per share at 2.0% yield Eligible shareholders must have bought the stock before 21 April 2023. Payment date: 27 April 2023. Payout ratio is a comfortable 52% but the company is paying out more than the cash it is generating. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.6%). Recent Insider Transactions • Feb 15
CEO, President & Director recently bought €489k worth of stock On the 13th of February, Joacim Lindoff bought around 138k shares on-market at roughly €3.54 per share. This transaction increased Joacim's direct individual holding by 6x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Joacim has been a buyer over the last 12 months, purchasing a net total of €782k worth in shares. Recent Insider Transactions • Feb 03
Independent Chairman of the Board recently bought €175k worth of stock On the 1st of February, Johan Malmquist bought around 50k shares on-market at roughly €3.50 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Johan has been a buyer over the last 12 months, purchasing a net total of €598k worth in shares. Reported Earnings • Jan 26
Full year 2022 earnings released: EPS: kr1.64 (vs kr2.72 in FY 2021) Full year 2022 results: EPS: kr1.64 (down from kr2.72 in FY 2021). Revenue: kr9.98b (up 10.0% from FY 2021). Net income: kr447.0m (down 40% from FY 2021). Profit margin: 4.5% (down from 8.2% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Annonce • Jan 26
Arjo AB (publ) Proposes Dividend for the Year 2022, Payable on April 27, 2023 Arjo AB (publ) proposed dividend per share of SEK 0.85 (SEK 1.15) for the year 2022. The total dividend thus amounts to SEK 232 million compared to SEK 313 million an year ago. The Board's proposed record date is April 24, 2023. Euroclear expects to distribute the dividend to shareholders from April 27, 2023. Annonce • Jan 25
Arjo AB (publ) Provides Organic Sales Guidance for the Year 2023 Arjo AB (publ) provided organic sales guidance for the year 2023. The company expects an organic sales growth for 2023 in line with its 3-5% target. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €3.24, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 28x in the Medical Equipment industry in Europe. Total loss to shareholders of 23% over the past three years. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Eva Elmstedt was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 29
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr2.52b (up 12% from 3Q 2021). Net income: kr86.0m (down 55% from 3Q 2021). Profit margin: 3.4% (down from 8.4% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Annonce • Oct 28
Arjo AB (publ) Updates Sales Guidance for the Full Year 2022 Arjo AB (publ) updated sales guidance for the full year 2022. The company announced that given the current uncertainty in the world, especially in the US, it is adjusting its outlook for the full year. Based on current information the company estimate that organic net sales growth for the full-year 2022 will be around 0%. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment deteriorated over the past week After last week's 24% share price decline to €5.09, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total returns to shareholders of 49% over the past three years. Reported Earnings • Jul 15
Second quarter 2022 earnings released: EPS: kr0.38 (vs kr0.69 in 2Q 2021) Second quarter 2022 results: EPS: kr0.38 (down from kr0.69 in 2Q 2021). Revenue: kr2.40b (up 9.3% from 2Q 2021). Net income: kr104.0m (down 45% from 2Q 2021). Profit margin: 4.3% (down from 8.6% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.1%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Apr 30
CEO, President & Director recently bought €99k worth of stock On the 27th of April, Joacim Lindoff bought around 14k shares on-market at roughly €7.20 per share. In the last 3 months, they made an even bigger purchase worth €480k. Joacim has been a buyer over the last 12 months, purchasing a net total of €668k worth in shares. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: kr0.60 (vs kr0.64 in 1Q 2021) First quarter 2022 results: EPS: kr0.60 (down from kr0.64 in 1Q 2021). Revenue: kr2.37b (up 9.3% from 1Q 2021). Net income: kr164.0m (down 5.2% from 1Q 2021). Profit margin: 6.9% (down from 8.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.3%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 32% per year. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Eva Elmstedt was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Annonce • Apr 23
Arjo AB (publ) Approves Dividend for the Year 2021 Arjo AB (publ) announced that at its Annual General Meeting was held on April 22, 2022, the company declared a dividend of SEK 1.15 per share. 26 April 2022 was determined as record date for dividend. Upcoming Dividend • Apr 18
Upcoming dividend of kr1.15 per share Eligible shareholders must have bought the stock before 25 April 2022. Payment date: 29 April 2022. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of German dividend payers (3.9%). Higher than average of industry peers (1.1%). Buying Opportunity • Feb 08
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 34%. The fair value is estimated to be kr10.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 31% per annum over the last 3 years. Recent Insider Transactions • Feb 06
CEO, President & Director recently bought €480k worth of stock On the 4th of February, Joacim Lindoff bought around 57k shares on-market at roughly €8.50 per share. This was the largest purchase by an insider in the last 3 months. Joacim has been a buyer over the last 12 months, purchasing a net total of €668k worth in shares. Reported Earnings • Feb 04
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: kr2.72 (up from kr1.93 in FY 2020). Revenue: kr9.07b (flat on FY 2020). Net income: kr742.0m (up 41% from FY 2020). Profit margin: 8.2% (up from 5.8% in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.8%, compared to a 14% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Annonce • Feb 03
Arjo AB (Publ) Proposes Dividend for the Year 2021, Payable on April 29, 2022 Arjo AB (publ) proposed a dividend for 2021 of SEK 1.15 per share (0.85), an increase of 35.3% compared with the preceding year. The total dividend thus amounts to SEK 313 million. The proposed dividend for 2021 is well in line with the target in Arjo's adopted dividend policy. The Board's proposed record date is April 26, 2022. Euroclear expects to distribute the dividend to shareholders from April 29, 2022. Recent Insider Transactions • Nov 10
Independent Director recently bought €156k worth of stock On the 8th of November, Ulf Grunander bought around 13k shares on-market at roughly €11.96 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €489k more in shares than they have sold in the last 12 months. Reported Earnings • Oct 29
Third quarter 2021 earnings released The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr2.25b (up 4.9% from 3Q 2020). Net income: kr189.0m (up 43% from 3Q 2020). Profit margin: 8.4% (up from 6.2% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 16
Second quarter 2021 earnings released: EPS kr0.69 (vs kr0.42 in 2Q 2020) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: kr2.20b (down 2.9% from 2Q 2020). Net income: kr189.0m (up 66% from 2Q 2020). Profit margin: 8.6% (up from 5.0% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 45% per year whereas the company’s share price has increased by 47% per year. Annonce • Apr 29
Arjo AB (Publ) Resolves to Declare A Dividend Arjo AB (publ) at the Annual General Meeting resolved to declare a dividend of SEK 0.85 per share. 29 April 2021 was determined as record date for dividend. Annonce • Apr 28
Arjo AB (Publ) Provides Sales Guidance for the Year 2021 Arjo AB (publ) provided sales guidance for the year 2021. Organic sales growth for 2021 is expected to be within the Group's target interval 3% to 5%. Upcoming Dividend • Apr 21
Upcoming dividend of kr0.85 per share Eligible shareholders must have bought the stock before 28 April 2021. Payment date: 04 May 2021. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (3.2%). In line with average of industry peers (1.0%). Reported Earnings • Mar 27
Full year 2020 earnings released: EPS kr1.93 (vs kr1.48 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr9.08b (up 1.1% from FY 2019). Net income: kr526.0m (up 31% from FY 2019). Profit margin: 5.8% (up from 4.5% in FY 2019). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth. 
